All In Biotech

Drug Trial Radar · NCT06878664

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Randomized Interval Assessment Trial of Lu177-Dotatate Every 8 Versus Every 16 Weeks in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (NETs) to Lower TOxicity

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

166

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
First posted
Mar 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized Phase II/late phase I de-escalation clinical trial with approved investigational medicinal products in new use condition, low intervention. Disease under study Patients with unresectable or metastatic, slowly progressive, well-differentiated (Grade1 and Grade2), somatostatin receptor-positive midgut neuroendocrine tumors (GEP-NETs). It is planned to randomize 166 patients with a histologically confirmed diagnosis of slowly progressive grade 1 or grade 2 advanced midgut neuroendocrine tumors (NETs) candidates to receive 177Lu-Dotatate targeted radioligand therapy (RLT). Patients are required to have SSTR+ disease, as evidenced on somatostatin receptor imaging. Patients will be randomized into two arms: 1. control arm: regimen 177Lu-Dotatate every 8 weeks (q8w) 2. experimental arm: regimen 177Lu-Dotatate every 16 weeks (q16w) Research hypothesis: Less intensive somatostatin-receptor (SST) targeted radioligand therapy (RLT) (7.4 GBq/cycle 177Lu-Dotatate every 16 weeks x 4 cycles) is associated with less severe hematological toxicities and may mitigate the risk to develop therapy-related myeloid neoplasms (t-MN) with similar antitumor efficacy in slowly growing gastrointestinal grade 1-2 NETs.

Conditions

  • Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

Interventions

  • 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.Drug

    Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks 177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate. 177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion. One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration.

  • 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.Drug

    Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles 177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate. Synonyms are: 177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE LUTATHERA, lutetium (177Lu) oxodotreotide 177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration.

  • Amino acid solutionDrug

    Renal protection starting 30 minutes before RLT and lasting 4 hours (iv) amino acid solution of 14.4-20 g of lysine and 14.9-20.7 g of arginine in 1 to 2 liters of solution)

  • Lanreotide (Autogel formulation) or Octreotide LARDrug

    Long-acting standard doses of SSA (Lanreotide autogel 120 mg subcutaneous (sc) or Octreotide LAR 30 mg im, starting 24h after RLT and every 4 weeks during RLT (q16w interval SSA administration should be adjusted to RLT administrations so that SSA is always given 24h after each RLT dose and at least 4 weeks prior to next RLT administration cycle) and q4w following last RLT administration until disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Grade 2-5 hematological toxicityTime frame: Throughout the study period, from initiation of treatment with RLT up to 24 months

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Centre François BACLESSE

    Caen, Caen, France · Recruiting

  • Chu Dijon

    Dijon, Dijon, France · Recruiting

  • Hospital Center University De Lille

    Lille, Lille, France · Recruiting

  • Hospices Civiles de Lyon

    Lyon, Lyon, France · Recruiting

  • Institut Paoli Calmette

    Marseille, Marseille, France · Not yet recruiting

  • Hopital BEAUJON

    Clichy, Paris, France · Recruiting

  • Hopital COCHIN

    Paris, Paris, France · Recruiting

  • Institute Gustave Roussy

    Villejuif, Paris, France · Recruiting

  • Centre Eugène MARQUIS

    Rennes, Rennes, France · Not yet recruiting

  • Hospital Universitari Vall d'Hebrón

    Barcelona, Barcelona, Spain · Recruiting

  • Instituto Catalán de Oncología - Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

  • Hospital Universitario de Burgos

    Burgos, Castille and León, Spain · Recruiting

  • Hospital Virgen de las Nieves de Granada

    Granada, Granada, Spain · Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Spain · Recruiting

  • Hospital 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias, Spain · Recruiting

  • Hospital Universitario Virgen del Rocío

    Seville, Sevilla, Spain · Recruiting

  • Hospital Clínico de Valencia

    Valencia, Valencia, Spain · Recruiting

  • Hospital Universitario y Politécnico La Fe

    Valencia, Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.